Tagrisso 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FM1ZX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,815
Award facts
- Contract value 100% obligated
- $14,815.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 8, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $14,815.21 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 40 mg tablets (30-unit package). This firm fixed-price, competitively awarded contract is scheduled for completion by January 30, 2026 and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. providing organizational oversight. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
TAGRISSO (osimertinib) is an oncology medication used in the treatment of non-small cell lung cancer, reflecting the Defense Health Agency's medical supply requirements for military treatment facilities and related healthcare systems. This delivery order represents a routine pharmaceutical procurement transaction within AmerisourceBergen's established role as a critical federal pharmaceutical vendor. The company's extensive IDC with DLA enables efficient fulfillment of time-sensitive medical supply needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices, supporting the Department of Defense's healthcare delivery infrastructure globally.
Quick answers
Who was awarded contract SPE2DR26FM1ZX?
SPE2DR26FM1ZX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FM1ZX worth?
The government has obligated $14,815 on SPE2DR26FM1ZX.
Is contract SPE2DR26FM1ZX an order under another contract?
Yes. SPE2DR26FM1ZX is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM1ZX competed?
The extent of competition for SPE2DR26FM1ZX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award